Real-World use of a clotting factor drug in iraqi hemophilia patients under review

NCT ID NCT06574984

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study observes how turoctocog alfa, a clotting factor medicine, is actually used in routine care for people with hemophilia A in Iraq. Researchers will review medical records from about 900 male patients to track bleeding rates and treatment patterns. The study does not change how patients are treated—it simply collects existing data to better understand real-world management.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Basrah Haemoplhilia centre

    NOT_YET_RECRUITING

    Basra, 61001, Iraq

  • Hilla Haemophilia centre

    ENROLLING_BY_INVITATION

    Hillah, 51001, Iraq

  • Karbala Haemophilia centre

    ENROLLING_BY_INVITATION

    Karbala, 56001, Iraq

  • Kirkuk Centre for Cancer and Blood Disorders

    ENROLLING_BY_INVITATION

    Kirkuk, 36001, Iraq

  • Najaf Haemophilia Centre

    ENROLLING_BY_INVITATION

    Najaf, 54001, Iraq

  • National centre for Hamophilia

    ENROLLING_BY_INVITATION

    Baghdad, 10001, Iraq

  • Novo Nordisk Investigational Site

    RECRUITING

    Baghdad, Iraq

Conditions

Explore the condition pages connected to this study.